Benlysta is the first drug approved to target B-lymphocyte stimulator protein (BLyS) for the treatment of systemic lupus erythematosus. It works by blocking the binding of BLyS to its receptors on B cells, inhibiting the survival of autoreactive B cells. The recommended dosing of Benlysta is 10 mg/kg administered intravenously every two weeks for the first three doses and every four weeks thereafter. Side effects include infections, psychological effects, and infusion reactions. Its benefits for patients appear marginal and it may increase cancer risk by reducing immune system activity.